Patent intelligence · US
US 11596660
Methods of treating bladder cancer
Methods of treating bladder cancer
Patent details — US 11596660
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 7, 2023
- Expiration
- Mar 2, 2043
- Applicant
- CG ONCOLOGY, INC.
- Claims
- 29
- CPC classes
- A61K, A61K35/76, A61K35/761, A61K35/768
Quick answer
US 11596660 (Methods of treating bladder cancer) is held by CG ONCOLOGY, INC.. Status: granted. Granted Mar 7, 2023. Expires Mar 2, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- CG ONCOLOGY, INC.
- Grant date
- Expiration
- Claims
- 29
- CPC classes
- A61K, A61K35/76, A61K35/761, A61K35/768, A61K9/0034, A61P
More from CG ONCOLOGY, INC.
Related pharmaceutical patents in our USPTO index.
-
US 12370229
Methods of treating bladder cancer
granted -
US 12090183
Methods of treating solid or lymphatic tumors by combination therapy
granted -
US 11497781
Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
granted -
US 11338003
Methods of treating bladder cancer with an oncolytic virus
granted
Frequently asked questions
What is US patent 11596660?
US 11596660 (Methods of treating bladder cancer) is held by CG ONCOLOGY, INC.. Status: granted. Granted Mar 7, 2023. Expires Mar 2, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11596660?
CG ONCOLOGY, INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 5 pharmaceutical patents for this assignee.
When does US 11596660 expire?
Our index shows an expiration date of Mar 2, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.